Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for prevention of migraine in patients with migraine and medication overuse headache
CTR20210147Phase 3Completed
- Sponsor
- Lingbei Biopharma
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of eptinezumab in migraine, medication overuse headache (MOH), sponsored by Lingbei Biopharma. Started Mar 2021; status: completed.
02
Drugs
eptinezumab
03
Conditions
migrainemedication overuse headache (MOH)
Beyond the preview
Go deeper on CTR20210147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210147.